Issued Patents
US11376317B2, FcRn-targeted mucosal vaccination against Respiratory Syncytial Virus (RSV).
US20190359655, FcRn-targeted mucosal vaccination against influenza infections.
US20230181723, FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated diseases.
US9803216: Genetically-engineered Newcastle disease virus as an oncolytic agent, and methods of using same
US9476033: Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7510863: Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
US6908618: Production of novel bovine respiratory syncytial viruses from cDNAs
US9238683: Efficient mucosal vaccination mediated by the neonatal Fc receptor
US8906385: Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
US8338566: Characterization of BBK07 antigen of Borrelia burgdorferi and methods of use
US8580553: Phage-associated lytic enzymes for treatment of Bacillus anthracis and related conditions
US8389469: Bacteriophage lysins for Bacillus anthracis
US7838255: Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
US7582729: Nucleic acids and polypeptides of C.sub.1 bacteriophage and uses thereof
US7582291: Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7569223: Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related condition
US7402309: Phage-associated lytic enzymes for treatment of Bacillus anthracis and related conditions
US6833262: A polypeptide having amidolytic activity for a serpin
US6608187: C1 bacteriophage lytic system
US7244558B1: Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated vaccines
US10383936B2: Infectious Laryngotracheitis Virus (ILTV) vaccine using recombinant Newcastle Disease Virus Vector
